Key result
HOCM is not associated with a difference in all-cause mortality compared to HNCM.
Why the study?
Whether LVOT obstruction is a reliable risk indicator of sudden cardiac death in HCM remains doubtful due to dynamic gradients and confounding factors.
Population
1810 HCM patients across 13 tertiary hospitals
Comparison
HOCM vs HNCM
Design
Multicenter propensity score-matched cohort study
Authors
Loading...
HOCM shows no mortality difference vs HNCM after matching; leaves open whether obstruction modifies prognosis or warrants targeted intervention.
Cohort (n=1,810)
Yes
p-value: p=0.22
He et al. (2023) conducted a cohort in Hypertrophic Cardiomyopathy (n=1,810). Hypertrophic Obstructive Cardiomyopathy (HOCM) vs. Hypertrophic Nonobstructive Cardiomyopathy (HNCM) was evaluated on All-cause mortality (p=0.22). Hypertrophic obstructive cardiomyopathy was not associated with a significant difference in all-cause mortality compared to hypertrophic nonobstructive cardiomyopathy in a propensity-matched cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: